Evidence map›Paper›PMID 31447893›Full record

ArticleJournal of geriatric cardiology : JGC2019

Effects of febuxostat on atrial remodeling in a rabbit model of atrial fibrillation induced by rapid atrial pacing.

Yong-Yan Fan, Feng Xu, Chao Zhu, Wen-Kun Cheng, Jian Li, Zhao-Liang Shan, Yang Li, Yu-Tang Wang

Abstract read
In one paragraph

Article in Journal of geriatric cardiology : JGC, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Therapeutic advances in atrial fibrillation based on animal models.Journal of Zhejiang University. Science. B · 2024
    Review
  2. Article
  3. Effects and pharmacological mechanism of Zhigancao Decoction on electrical and structural remodeling of the atrium of rabbits induced by rapid atrial pacing.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2023
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yong-Yan FanCollege of Medicine, Nankai University, Tianjin, China.
Feng XuDepartment of Bone & Joint, Shijingshan Teaching Hospital of Capital Medical University, Beijing Shijingshan Hospital, Beijing, China.
Chao ZhuDepartment of Heart Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Wen-Kun ChengDepartment of Cardiology, Chinese PLA General Hospital, Beijing, China.
Jian LiDepartment of Cardiology, Chinese PLA General Hospital, Beijing, China.
Zhao-Liang ShanDepartment of Cardiology, Chinese PLA General Hospital, Beijing, China.
Yang LiDepartment of Cardiology, Chinese PLA General Hospital, Beijing, China.
Yu-Tang WangCollege of Medicine, Nankai University, Tianjin, China.
Chinese PLA General Hospital · CNBeijing Friendship Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFebuxostat, a novel nonpurine selective inhibitor of xanthine oxidase (XO), may be used in the prevention and management of atrial fibrillation (AF). The purpose of this study was to evaluate the effects of febuxostat on atrial remodeling in a rabbit model of AF induced by rapid atrial pacing (RAP) and the mechanisms by which it acts.

methodsTwenty-four rabbits were randomly divided into four groups: sham-operated group (Group S), RAP group (Group P), RAP with 5 mg/kg per day febuxostat group (Group LFP), and RAP with 10 mg/kg per day febuxostat group (Group HFP). All rabbits except those in Group S were subjected to RAP at 600 beats/min for four weeks. The effects of febuxostat on atrial electrical and structural remodeling, markers of inflammation and oxidative stress, and signaling pathways involved in the left atrium were examined.

resultsShortened atrial effective refractory period (AERP), increased AF inducibility, decreased mRNA levels of Cav1.2 and Kv4.3, and left atrial enlargement and dysfunction were observed in Group P, and these changes were suppressed in the groups treated with febuxostat. Prominent atrial fibrosis was observed in Group P, as were increased levels of TGF-β1, Collagen I, and α-SMA and decreased levels of Smad7 and eNOS. Treatment with febuxostat attenuated these differences. Changes in inflammatory and oxidative stress markers induced by RAP were consistent with the protective effects of febuxostat.

conclusionsThis study is the first to find that febuxostat can inhibit atrial electrical and structural remodeling of AF by suppressing XO and inhibiting the TGF-β1/Smad signaling pathway.

Indexed as

Atrial fibrillationAtrial remodelingFebuxostatRapid atrial pacingXanthine oxidase

Identifiers

PMID31447893
PMCPMC6689522
OpenAlexW2966555867

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.